AIM: Accelerated atherosclerosis is a characteristic feature of chronic kidney disease (CKD). CD36 is a scavenger receptor which contributes to foam cell formation, an early crucial step in atherosclerosis development. Recently, a soluble form of CD36 (sCD36) has been discovered. The aim of the study was to develop an ELISA method for quantitative sCD36 evaluation and to measure it in a cohort of CKD stage 5 patients. METHOD: A novel monoclonal antibody-based sandwich ELISA for sCD36 evaluation was developed and verified by repeated optimization procedures. Serum concentration of sCD36 was then analyzed in a cohort of 228 CKD stage 5 patients prior to dialysis initiation. Additionally, samples from a control group of 73 healthy, age and gender-matched subjects were evaluated. RESULTS: The novel CD36 ELISA assay had a recovery of at least 90%, and intra- and inter-assay variability of 6 and 11%, respectively. Concentration of serum sCD36 in CKD patients was significantly increased as compared to controls, and associated with the use of HMG-CoA reductase inhibitors (statins) and the presence of diabetes mellitus (DM). Patients above the 75th percentile of sCD36 concentration were at increased risk of 3-year cardiovascular mortality, as compared to the rest of the cohort [HR 2.85 (1.09-7.59) p=0.03]. CONCLUSION: For the first time, sCD36 was assessed quantitatively in a group of patients and showed associations with DM, CKD, and statin use. Furthermore, the concentration of sCD36 predicted cardiovascular mortality in CKD stage 5 patients.
AIM: Accelerated atherosclerosis is a characteristic feature of chronic kidney disease (CKD). CD36 is a scavenger receptor which contributes to foam cell formation, an early crucial step in atherosclerosis development. Recently, a soluble form of CD36 (sCD36) has been discovered. The aim of the study was to develop an ELISA method for quantitative sCD36 evaluation and to measure it in a cohort of CKD stage 5 patients. METHOD: A novel monoclonal antibody-based sandwich ELISA for sCD36 evaluation was developed and verified by repeated optimization procedures. Serum concentration of sCD36 was then analyzed in a cohort of 228 CKD stage 5 patients prior to dialysis initiation. Additionally, samples from a control group of 73 healthy, age and gender-matched subjects were evaluated. RESULTS: The novel CD36 ELISA assay had a recovery of at least 90%, and intra- and inter-assay variability of 6 and 11%, respectively. Concentration of serum sCD36 in CKDpatients was significantly increased as compared to controls, and associated with the use of HMG-CoA reductase inhibitors (statins) and the presence of diabetes mellitus (DM). Patients above the 75th percentile of sCD36 concentration were at increased risk of 3-year cardiovascular mortality, as compared to the rest of the cohort [HR 2.85 (1.09-7.59) p=0.03]. CONCLUSION: For the first time, sCD36 was assessed quantitatively in a group of patients and showed associations with DM, CKD, and statin use. Furthermore, the concentration of sCD36 predicted cardiovascular mortality in CKD stage 5 patients.
Authors: L Knøsgaard; K Kazankov; N H Birkebæk; P Holland-Fischer; A Lange; J Solvig; A Hørlyck; K Kristensen; S Rittig; H Vilstrup; H Grønbæk; A Handberg Journal: Eur J Clin Nutr Date: 2016-06-08 Impact factor: 4.016
Authors: Robert A Koeth; Kamyar Kalantar-Zadeh; Zeneng Wang; Xiaoming Fu; W H Wilson Tang; Stanley L Hazen Journal: J Am Soc Nephrol Date: 2013-02-21 Impact factor: 10.121
Authors: David J Kennedy; Yiliang Chen; Wenxin Huang; Jamie Viterna; Jiang Liu; Kristen Westfall; Jian Tian; David J Bartlett; W H Wilson Tang; Zijian Xie; Joseph I Shapiro; Roy L Silverstein Journal: Hypertension Date: 2012-11-19 Impact factor: 10.190
Authors: Sudipta Biswas; Detao Gao; Jessica B Altemus; Umar R Rekhi; Ellen Chang; Maria Febbraio; Tatiana V Byzova; Eugene A Podrez Journal: Free Radic Biol Med Date: 2021-03-26 Impact factor: 7.376
Authors: Siobhan Bacon; Ma P Kyithar; Jasmin Schmid; Andre Costa Pozza; Aase Handberg; Maria M Byrne Journal: PLoS One Date: 2013-09-12 Impact factor: 3.240